The Translational Research Network for Prostate Cancer (TransPot) program adopts an innovative, multidisciplinary approach, providing highly sought-after, effective solutions for incurable prostate cancer (PC). The TransPot scientific objective is to obtain an unmatched depth of molecular, mechanistic and informatics systems-level disease understanding in order to improve the prognosis and treatment of lethal PC, aimed to (i) provide important insights into molecular mechanisms driving treatment resistant PC including castrate-resistant PC (CRPC), (ii) identify novel therapeutic targets, (iii) develop and validate predictive models for disease progression, prognosis and responsiveness to current and novel (co-)treatment options, and (iv) provide superior, clinically relevant tools and biomarker signatures for personalising and optimising CRPC therapy. Our research program is built on network-wide, state-of-the-art cancer biology-based mechanistic research integrated with a systems medicine approach: 1. Cancer biology-based mechanistic research incorporating a comprehensive range of model systems incorporating unique, pre-clinical and clinical resources and distinct phenotypic high content screen platforms. 2. A systems medicine approach with mathematical modelling to develop novel predictive/prognostic tools. 3. Centres of excellence in surgery, oncology and clinical trials, comprising clinical infrastructure and essential resources whereby candidate therapeutic targets and predictive/prognostic tools can be comprehensively evaluated, including accessing bio-repository resources. We will train young scientists to apply multiple ‘omics’ technologies and approaches in model systems and systems biology to answer important clinically-relevant questions. Advances achieved will facilitate personalized targeted-medicine in treating lethal PC, and will impact beyond the scientific community by improving the well-being of advanced PC patients.

The social and economic challenges of ageing populations and chronic disease can only be met by translation of biomedical discoveries to new, innovative and cost effective treatments. The ESFRI Biological and Medical Research Infrastructures (BMS RI) underpin every step in this process; effectively joining scientific capabilities and shared services will transform the understanding of biological mechanisms and accelerate its translation into medical care. Biological and medical research that addresses the grand challenges of health and ageing span a broad range of scientific disciplines and user communities. The BMS RIs play a central, facilitating role in this groundbreaking research: inter-disciplinary biomedical and translational research requires resources from multiple research infrastructures such as biobank samples, and resources from multiple research infrastructures such as biobank samples, imaging facilities, molecular screening centres or animal models. Through a user-led approach CORBEL will develop the tools, services and data management required by cutting-edge European research projects: collectively the BMS RIs will establish a sustained foundation of collaborative scientific services for biomedical research in Europe and embed the combined infrastructure capabilities into the scientific workflow of advanced users. Furthermore CORBEL will enable the BMS RIs to support users throughout the execution of a scientific project: from planning and grant applications through to the long-term sustainable management and exploitation of research data. By harmonising user access, unifying data management, creating common ethical and legal services, and offering joint innovation support CORBEL will establish and support a new model for biological and medical research in Europe. The BMS RI joint platform will visibly reduce redundancy and simplify project management and transform the ability of users to deliver advanced, cross-disciplinary research.

<< Objectives >>SCIBIOEU will:identify communication gaps between the general public and science; support citizens to better understand the aims of science and usefulness in their lives; support students and young scientists to be well-equipped in using effective science outreach strategies and to enrich their communication skills; develop an e-learning platform including the course that can be easily integrated in HEIs’ platforms;support teaching methods of HEIs and other institutions by offering a new course<< Implementation >>SCIBIOEU consist of five WPs. WP1. Project Management; WP2. Development of the course and the e-learning platform; WP3.Design and development of the Serious Game (SG); WP4. SCIBIOEU Training in practice; WP5. Dissemination Activities. The main activities of these WPs are: literature on existing courses; co-designed focus groups with final-users to determine their need for the course and the SG; development and translation of all the materials; testing the materials with final users in 4 pilots<< Results >>The main results of SCIBIOEU: 1. A new innovative course, adapted to the need of target groups, on Science Outreach of biobanking; 2. A SG as an attractive tool of awareness of general public in biobanking issues; 3. A digital Guideline Handbook called “Best Practise Guidelines for Science Outreach”. These results can be easily adapted to other scientific fields and thus they will be “prototypes” for professors of HEIs and scientists of research institutions who wish to organise science outreach

BBMRI-ERIC: the Biobanking and BioMolecular resources Research Infrastructure - European Research Infrastructure Consortium, aims to establish, operate and develop a Pan-European distributed research infrastructure in order to facilitate the access to biological resources as well as facilities and to support high quality biomolecular and biomedical research. The ADOPT BBMRI-ERIC proposal aims at boosting and accelerating implementation of BBMRI-ERIC and its services. Its main deliverables are designed to complete or launch the construction of key Common Services of the Research Infrastructure as required for ESFRI-projects "under implementation", reflecting the targets of the European Research Area (ERA). One of the challenges in the post-genomic era is the research on common complex diseases, such as cancer, diabetes and Alzheimer’s disease. Revealing these diseases will depend critically on the study of human biological samples and data from large numbers of patients and healthy individuals. The EU’s ageing population is will result in an increase in many of those diseases and consequently an increased healthcare expenditure for senior citizens. BBMRI-ERIC is a specific European asset having become a fundamental component in addressing the ongoing and future requirements particularly of Europe's health service frameworks, including competitiveness and innovativeness of health-related industries. Its implementation is essential for the understanding of the diversity of human diseases, biological samples and corresponding data, which are required for the development of any new drug or diagnostic assay and are, therefore, critical for the advancement in health research, ultimately leading to personalised medicine. BBMRI-ERIC will provide a gateway access to the collections of the European research community, expertise and services building on the outcome of ADOPT BBMRI-ERIC.